The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s disease.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published ...

Only two trials in the meta-analysis reported on BMD change. One trial found once-weekly exenatide 2 mg was associated with a greater increase in lumbar spine BMD at 3 months compared with placebo.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying ... assigned to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 ...